

Ramon Colomer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5455397/publications.pdf>

Version: 2024-02-01

258
papers

10,831
citations

31902

53
h-index

35952

97
g-index

271
all docs

271
docs citations

271
times ranked

12679
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. <i>Clinical and Translational Oncology</i> , 2022, 24, 483-494.	1.2	19
2	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	1.7	8
3	Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. <i>Cancers</i> , 2022, 14, 2898.	1.7	5
4	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	1.7	9
5	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 85-97.	5.1	64
6	Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. <i>Clinical and Translational Oncology</i> , 2021, 23, 1529-1541.	1.2	15
7	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
8	The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 610885.	1.3	10
9	46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study. <i>Annals of Oncology</i> , 2021, 32, S40-S41.	0.6	0
10	43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial. <i>Annals of Oncology</i> , 2021, 32, S38-S39.	0.6	3
11	1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy. <i>Annals of Oncology</i> , 2021, 32, S999-S1000.	0.6	0
12	Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychology</i> , 2021, 12, 755965.	1.1	17
13	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 254-264.	0.5	44
14	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020, 22, 124.	2.2	21
15	When should we order a next generation sequencing test in a patient with cancer?. <i>EClinicalMedicine</i> , 2020, 25, 100487.	3.2	94
16	Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 14877.	1.6	13
17	A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. , 2020, 8, e001187.		23
18	Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. <i>OncImmunology</i> , 2020, 9, 1751548.	2.1	27

#	ARTICLE	IF	CITATIONS
19	Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4687.	1.8	4
20	Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. , 2020, , .		4
21	PCN78 Costs of Recurrence in Patients with HER2+ Breast Cancer in Spain. <i>Value in Health</i> , 2020, 23, S435.	0.1	1
22	PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain. <i>Value in Health</i> , 2020, 23, S442.	0.1	0
23	Nivolumab-induced thyroid dysfunction in patients with lung cancer. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 26-34.	0.1	17
24	Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. <i>Nature Communications</i> , 2019, 10, 5011.	5.8	43
25	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019, 109, 21-27.	1.3	188
26	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. <i>Breast Cancer Research</i> , 2019, 21, 69.	2.2	16
27	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019, 18, e287-e293.	1.0	15
28	Nivolumab-induced thyroid dysfunction in patients with lung cancer. <i>Endocrinología y Diabetes Y Nutrición (English Ed)</i> , 2019, 66, 26-34.	0.1	1
29	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
30	A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, e45-e47.	0.5	5
31	BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 72.	0.9	4
32	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , 2019, 10, 4321-4332.	0.8	0
33	Real-world treatment in patients with HER2+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 197-205.	1.1	6
34	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826.	1.2	57
35	Predictors of unknown cancer in patients with ischemic stroke. <i>Journal of Neuro-Oncology</i> , 2018, 137, 551-557.	1.4	21
36	Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. <i>Annals of Oncology</i> , 2018, 29, 646-653.	0.6	150

#	ARTICLE	IF	CITATIONS
37	Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. <i>Melanoma Research</i> , 2018, 28, 562-570.	0.6	18
38	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab. <i>Annals of Oncology</i> , 2018, 29, v97.	0.6	0
39	PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN. <i>Value in Health</i> , 2018, 21, S18.	0.1	0
40	The impact of primary tumor location in patients with resected colorectal liver metastasis. <i>Annals of Oncology</i> , 2018, 29, v79.	0.6	0
41	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. <i>Nature Communications</i> , 2018, 9, 3501.	5.8	45
42	Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival. <i>Annals of Oncology</i> , 2018, 29, v46.	0.6	5
43	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15505-e15505.	0.8	0
44	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
45	Advanced breast cancer clinical nursing curriculum: review and recommendations. <i>Clinical and Translational Oncology</i> , 2017, 19, 251-260.	1.2	16
46	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
47	P2.02-027 Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2108-S2109.	0.5	6
48	P1.01-057 Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1916-S1917.	0.5	0
49	Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?. <i>Annals of Oncology</i> , 2017, 28, v30-v31.	0.6	0
50	Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer. , 2017, , .		1
51	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	0.8	43
52	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	0.8	14
53	Abstract P3-12-05: Estimating costs of relapsing HER2+ breast cancer in Spain. , 2017, , .		0
54	Abstract P3-12-02: Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+ breast cancer in Spain. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
55	Estimated Costs of Locoregional and Metastatic Recurrences in Patients with HER2+ Breast Cancer in Spain. Value in Health, 2016, 19, A729.	0.1	1
56	Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain. Value in Health, 2016, 19, A740.	0.1	0
57	Response to Targeted Therapy and Healthcare Resource Utilization (HRU): A European Retrospective Chart Review Study in Patients With HER2+ Metastatic Breast Cancer. Value in Health, 2016, 19, A742.	0.1	0
58	Treatment Rates in Patients with HER2+ Metastatic Breast Cancer and the Factors Influencing Treatment Decision. Value in Health, 2016, 19, A764-A765.	0.1	1
59	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 1557.	3.4	242
60	Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?. Journal of Clinical Oncology, 2016, 34, 3226-3227.	0.8	2
61	Exploiting cross-talk between lipid metabolism and oncogenic signaling for treatment of ovarian cancer. European Journal of Cancer, 2016, 61, S61.	1.3	0
62	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. Current Drug Targets, 2016, 18, 147-159.	1.0	55
63	Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors. Current Drug Targets, 2016, 17, 1735-1746.	1.0	4
64	Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).. Journal of Clinical Oncology, 2016, 34, TPS615-TPS615.	0.8	0
65	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. International Journal of Cancer, 2015, 136, 2078-2090.	2.3	60
66	269 Molecular interplay between cancer cell fatty acid metabolism and oncogenic signaling as resource for novel treatment strategies against ovarian cancer. European Journal of Cancer, 2015, 51, S49.	1.3	0
67	Dermatofibrosarcoma Protuberans with Lung Metastasis Requiring Pneumonectomy. Rare Tumors, 2015, 7, 166-168.	0.3	3
68	A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms. EBioMedicine, 2015, 2, 778-779.	2.7	4
69	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEFERTT).. Journal of Clinical Oncology, 2015, 33, 610-610.	0.8	3
70	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Oncotarget, 2015, 6, 7104-7122.	0.8	17
71	Abstract 1493: 18F-misonidazole PET (FMISO-PET) monitors vascular normalization (VN) and predicts benefit from antiangiogenic treatment plus chemotherapy in pancreas cancer. , 2015, , .		0
72	Selective activity over a constitutively active RET variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-IBR002 phase I trial. Molecular Oncology, 2014, 8, 1719-1728.	2.1	3

#	ARTICLE	IF	CITATIONS
73	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). British Journal of Cancer, 2014, 111, 1060-1064.	2.9	26
74	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clinical and Translational Oncology, 2013, 15, 477-483.	1.2	12
75	Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. Supportive Care in Cancer, 2013, 21, 3039-3049.	1.0	9
76	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, The, 2013, 381, 805-816.	6.3	1,664
77	In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. British Journal of Cancer, 2013, 108, 1298-1305.	2.9	6
78	Dovitinib lactate. Drugs of the Future, 2013, 38, 81.	0.0	2
79	Abstract PD5-8: Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010/GEICAM 2010-10 study. , 2013, , .		0
80	Abstract P3-10-02: The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM). , 2013, , .		0
81	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Annals of Oncology, 2012, 23, 625-631.	0.6	106
82	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Investigational New Drugs, 2012, 30, 880-888.	1.2	19
83	New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer Activity. Journal of Medicinal Chemistry, 2012, 55, 5013-5023.	2.9	57
84	A new multidisciplinary Spanish Working Group on Cancer Biomarkers: presentation and aims. Clinical and Translational Oncology, 2012, 14, 323-324.	1.2	0
85	3D Assessment of Lymph Nodes vs. RECIST 1.1. Academic Radiology, 2011, 18, 391-394.	1.3	10
86	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. European Respiratory Journal, 2011, 37, 624-631.	3.1	304
87	Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico. Revista Española De Patología, 2011, 44, 32-48.	0.6	6
88	A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Research, 2011, 13, R131.	2.2	75
89	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. Breast, 2011, 20, S43.	0.9	4
90	Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Supportive Care in Cancer, 2011, 19, 657-666.	1.0	23

#	ARTICLE	IF	CITATIONS
91	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 179-184.	1.2	75
92	Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. <i>Clinical and Translational Oncology</i> , 2011, 13, 636-651.	1.2	16
93	Prediction of Response to Targeted Therapies in Lung Cancer Using Dynamic Imaging: Still Far From Clinical Implementation. <i>Journal of Clinical Oncology</i> , 2011, 29, 3716-3718.	0.8	2
94	Selection of extreme phenotypes: the role of clinical observation in translational research. <i>Clinical and Translational Oncology</i> , 2010, 12, 174-180.	1.2	34
95	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286.	1.2	2
96	Targeting cytoskeleton reorganisation as antimetastatic treatment. <i>Clinical and Translational Oncology</i> , 2010, 12, 662-669.	1.2	12
97	Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2 ⁺ breast cancer. <i>Annals of the New York Academy of Sciences</i> , 2010, 1210, 86-92.	1.8	27
98	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated. <i>Journal of Clinical Oncology</i> , 2010, 28, 960-966.	0.8	37
99	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.	0.6	41
100	Antimicrobial cyclic decapeptides with anticancer activity. <i>Peptides</i> , 2010, 31, 2017-2026.	1.2	23
101	Relationship of breast cancer stem cells (CSCs) and chronic O ₂ /glucose deprivation (C-OGD).. <i>Journal of Clinical Oncology</i> , 2010, 28, 10509-10509.	0.8	0
102	Prevalence and management of anemia in patients with non-myeloid tumors undergoing systemic therapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, e19658-e19658.	0.8	0
103	Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. <i>Clinical Cancer Research</i> , 2009, 15, 7608-7615.	3.2	85
104	Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 351-358.	1.1	10
105	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	1.2	15
106	Congress of the Spanish Society of Medical Oncology (SEOM) in Barcelona. <i>Clinical and Translational Oncology</i> , 2009, 11, 707-707.	1.2	1
107	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	1.2	3
108	Development of a New Questionnaire to Assess Patient Perceptions of Cancer-Related Fatigue: Item Generation and Item Reduction. <i>Value in Health</i> , 2009, 12, 130-138.	0.1	18

#	ARTICLE	IF	CITATIONS
109	Creatine transporter deficiency in two adult patients with static encephalopathy. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 91-96.	1.7	13
110	Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM). <i>Revista Española De Patología</i> , 2009, 42, 3-16.	0.6	6
111	MG28, a novel fatty acid synthase inhibitor, overcomes resistance to anti-HER therapies in breast cancer.., 2009, , .		0
112	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 471-479.	1.1	98
113	Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. <i>Clinical and Translational Oncology</i> , 2008, 10, 30-34.	1.2	17
114	Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 52-57.	1.2	7
115	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 10, 219-226.	1.2	0
116	Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 367-371.	1.2	39
117	BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 157-163.	1.3	65
118	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <i>Cell Proliferation</i> , 2008, 41, 59-85.	2.4	160
119	Novel chemotherapy approaches in chemoradiation protocols. <i>Gynecologic Oncology</i> , 2008, 110, S45-S48.	0.6	14
120	PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY: THE CASE OF THE PERFORM QUESTIONNAIRE. <i>Value in Health</i> , 2008, 11, A486.	0.1	0
121	Review of gemcitabine plus taxane combination therapy in the first-line treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 9-12.	2.2	1
122	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 811-816.	3.2	113
123	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008, 19, 420-432.	0.6	410
124	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human breast carcinoma cells. <i>Annals of Oncology</i> , 2008, 19, 1097-1109.	0.6	39
125	Her-2/neu-induced Cytokine Signature in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 311-319.	0.8	16
126	Determining the clinical significance of the improvement in health-related quality of life (HRQoL) measures in oncology patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 20622-20622.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. <i>Anticancer Research</i> , 2008, 28, 3671-6.	0.5	32
128	Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007, 10, 27-39.	1.0	12
129	n-3 Fatty acids, cancer and cachexia: a systematic review of the literature. <i>British Journal of Nutrition</i> , 2007, 97, 823-831.	1.2	219
130	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007, 18, 973.	1.2	24
131	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin [®] , [®]) by transcriptionally inhibiting $\hat{\epsilon}$ HER2 super-expression [™] occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. <i>International Journal of Oncology</i> , 2007, 31, 769.	1.4	15
132	Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. <i>European Journal of Cancer</i> , 2007, 43, 144-148.	1.3	69
133	Protein array technology to detect HER2 (erbB-2)-induced $\hat{\epsilon}$ cytokine signature [™] in breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 1117-1124.	1.3	83
134	728 POSTER Differential inhibitory effects of epigallocatechin-3-gallate (EGCG) and C75 in cancer fatty acid metabolism. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 115.	2.2	0
135	2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 215.	2.2	1
136	EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt. <i>Neoplasia</i> , 2007, 9, 614-624.	2.3	42
137	PCN68 SENSITIVITY TO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE. <i>Value in Health</i> , 2007, 10, A343-A344.	0.1	0
138	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor $\hat{\epsilon}$ positive metastatic breast cancer: A confirmatory prospective study. <i>Cancer</i> , 2007, 110, 2178-2185.	2.0	14
139	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin [®] , [®]) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007, 7, 80.	1.1	154
140	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 375-84.	1.2	3
141	Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. <i>Journal of Clinical Oncology</i> , 2007, 25, 4613-4613.	0.8	37
142	Validation of a new questionnaire to assess the patient perception of cancer-related fatigue (CRF): The Perform Questionnaire (PQ). <i>Journal of Clinical Oncology</i> , 2007, 25, 19533-19533.	0.8	2
143	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007, 20, 3-10.	1.8	96
144	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to		

#	ARTICLE	IF	CITATIONS
145	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007, 18, 973-80.	1.2	39
146	554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cells. <i>European Journal of Cancer</i> , Supplement, 2006, 4, 168.	2.2	1
147	CN2 USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE. <i>Value in Health</i> , 2006, 9, A203.	0.1	0
148	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006, 64, S40-S52.	2.6	21
149	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.	1.2	15
150	Mediterranean diet, olive oil and cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 15-21.	1.2	93
151	HER2 (erbB-2)-targeted effects of the ω -3 polyunsaturated. Fatty acid ω -3-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". <i>Clinical and Translational Oncology</i> , 2006, 8, 812-820.	1.2	66
152	Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. <i>Clinical and Translational Oncology</i> , 2006, 8, 896-902.	1.2	10
153	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006, 64, 40-52.	2.6	10
154	Access to specialized cancer care and clinical trials for cancer patients from non-urban areas is facilitated by a Cancer Network organization. <i>Journal of Clinical Oncology</i> , 2006, 24, 16006-16006.	0.8	1
155	Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4089-4089.	0.8	12
156	Gemcitabine in Combination with Paclitaxel for the Treatment of Metastatic Breast Cancer. <i>Women's Health</i> , 2005, 1, 323-329.	0.7	9
157	Exogenous supplementation with ω -3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. <i>European Journal of Cancer Prevention</i> , 2005, 14, 263-270.	0.6	84
158	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin [®]) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005, 16, 359-371.	0.6	197
159	International conference on the healthy effect of virgin olive oil. <i>European Journal of Clinical Investigation</i> , 2005, 35, 421-424.	1.7	248
160	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. <i>International Journal of Cancer</i> , 2005, 115, 19-35.	2.3	100
161	Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 291-293.	1.3	21
162	Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2005, 7, 515-517.	1.2	44

#	ARTICLE	IF	CITATIONS
163	Effect of $\hat{1}^3$ -Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. Journal of the National Cancer Institute, 2005, 97, 1611-1615.	3.0	36
164	It Is Not Time to Stop Progesterone Receptor Testing in Breast Cancer. Journal of Clinical Oncology, 2005, 23, 3868-3869.	0.8	40
165	Growth and Molecular Interactions between Tamoxifen and Trastuzumab. Clinical Cancer Research, 2005, 11, 3597-3597.	3.2	0
166	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. International Journal of Oncology, 2005, 26, 1507.	1.4	5
167	What is the best schedule for administration of gemcitabine-taxane?. Cancer Treatment Reviews, 2005, 31, S23-S28.	3.4	16
168	Gemcitabine plus taxane combinations in metastatic breast cancer:a comprehensive review. European Journal of Cancer, Supplement, 2005, 3, 9-16.	2.2	4
169	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of $\hat{1}^3$ -linolenic acid-induced toxicity to tumor cells: an extension to Nwankwoâ€™s hypothesis. Medical Hypotheses, 2005, 64, 337-341.	0.8	23
170	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. Medical Hypotheses, 2005, 64, 342-349.	0.8	62
171	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. Molecular Genetics and Metabolism, 2005, 84, 293-295.	0.5	16
172	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. Breast Cancer Research, 2005, 7, 1.	2.2	0
173	Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. Journal of Clinical Oncology, 2005, 23, 3176-3176.	0.8	6
174	Targeting fatty acid synthase: Potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. Drug News and Perspectives, 2005, 18, 375.	1.9	66
175	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. International Journal of Oncology, 2005, 26, 1507-15.	1.4	9
176	Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM). Journal of Clinical Oncology, 2004, 22, 961-962.	0.8	16
177	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Annals of Oncology, 2004, 15, 1719-1721.	0.6	25
178	Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Annals of Oncology, 2004, 15, 201-206.	0.6	80
179	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF- $\hat{1}^B$. International Journal of Oncology, 2004, 24, 591.	1.4	36
180	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Annals of Oncology, 2004, 15, 1749-1759.	0.6	90

#	ARTICLE	IF	CITATIONS
181	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10715-10720.	3.3	297
182	Cancer care in rural areas. British Journal of Cancer, 2004, 90, 1688-1688.	2.9	0
183	Management of metastatic breast cancer: are we prepared to cope with our own success?. British Journal of Cancer, 2004, 91, 2101-2101.	2.9	0
184	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). Breast Cancer Research and Treatment, 2004, 84, 183-195.	1.1	71
185	Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 86, 125-137.	1.1	47
186	Dietary interventions in cancer. Clinical and Translational Oncology, 2004, 6, 496-500.	1.2	2
187	Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer, 2004, 100, 1833-1842.	2.0	17
188	γ -6 Polyunsaturated fatty acid γ -linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: γ -Linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. International Journal of Cancer, 2004, 109, 949-954.	2.3	22
189	Gemcitabine- and taxane-based protocols in breast cancer. American Journal of Cancer, 2004, 3, 19-20.	0.4	0
190	Dose and Dose Intensity Effect of Adjuvant Anthracycline-Based Chemotherapy in Early Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 269-273.	0.6	2
191	γ -6 polyunsaturated fatty acid γ -linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports, 2004, 11, 1241.	1.2	16
192	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. Journal of Clinical Oncology, 2004, 22, 507-507.	0.8	2
193	Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Journal of Clinical Oncology, 2004, 22, 544-544.	0.8	18
194	Microarray gene expression analysis of fatty acid synthase (FAS) signaling on breast cancer cell lines. Journal of Clinical Oncology, 2004, 22, 9690-9690.	0.8	2
195	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. Journal of Clinical Oncology, 2004, 22, 507-507.	0.8	12
196	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF- κ B. International Journal of Oncology, 2004, 24, 591-608.	1.4	41
197	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports, 2004, 11, 1241-52.	1.2	43
198	Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic) but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. International Journal of Oncology, 2004, 24, 1369-83.	1.4	26

#	ARTICLE	IF	CITATIONS
199	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. <i>Oncology Reports</i> , 2004, 12, 411-22.	1.2	29
200	Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 740-740.	0.8	0
201	A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 286-291.	1.1	6
202	Primary aortic sarcoma with widespread vascular embolic metastases. <i>European Journal of Internal Medicine</i> , 2003, 14, 258-261.	1.0	9
203	CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner. <i>Journal of Experimental Medicine</i> , 2003, 198, 1381-1389.	4.2	129
204	Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2003, 14, 783-787.	0.6	17
205	Modulation of EGFR and neu expression by n-6 and n-9 high-fat diets in experimental mammary adenocarcinomas. <i>Oncology Reports</i> , 2003, 10, 1417.	1.2	8
206	Modulation of EGFR and neu expression by n-6 and n-9 high-fat diets in experimental mammary adenocarcinomas. <i>Oncology Reports</i> , 2003, 10, 1417-24.	1.2	26
207	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. <i>International Journal of Oncology</i> , 2002, 21, 745.	1.4	26
208	Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1054-1065.	3.0	138
209	Does HER-2 Status Predict Only a Decreased Response to Hormone Therapy in Advanced Breast Cancer, or Does It Also Predict the Extent of Metastatic Disease?. <i>Journal of Clinical Oncology</i> , 2002, 20, 4605-4606.	0.8	3
210	Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer Cells. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 203-219.	1.1	68
211	Effects of dietary fatty acids on the proliferation, adhesion and metastatic potential of breast cancer cells: an experimental review. , 2002, 4, 77-84.		0
212	Dose intensity and clinical response in head and neck carcinoma treated with cisplatin + 5-fluorouracil. , 2002, 4, 485-490.		1
213	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. <i>International Journal of Oncology</i> , 2002, 21, 745-53.	1.4	16
214	Combined treatment with biphosphonates, low-dose chemotherapy, and trastuzumab in receptor-negative breast cancer patients with bone marrow involvement. <i>European Journal of Internal Medicine</i> , 2001, 12, 462-463.	1.0	1
215	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. <i>European Journal of Cancer</i> , 2001, 37, 402-413.	1.3	124
216	Prognostic Value of Cytosolic p53 Protein in Breast Cancer. <i>Tumor Biology</i> , 2001, 22, 337-344.	0.8	18

#	ARTICLE	IF	CITATIONS
217	Herceptin: From the Bench to the Clinic. <i>Cancer Investigation</i> , 2001, 19, 49-56.	0.6	44
218	High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma. <i>Cancer</i> , 2001, 92, 2508-2516.	2.0	8
219	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. <i>Bone Marrow Transplantation</i> , 2001, 27, 117-123.	1.3	3
220	Doxorubicin and paclitaxel in advanced breast carcinoma. <i>Cancer</i> , 2000, 89, 2169-2175.	2.0	24
221	Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. <i>Seminars in Oncology</i> , 2000, 27, 20-4.	0.8	7
222	Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. <i>Clinical Cancer Research</i> , 2000, 6, 2356-62.	3.2	120
223	p53 Expression in Locally Advanced Pharyngeal Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 1999, 125, 1356.	1.5	8
224	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. <i>Cancer</i> , 1999, 85, 213-219.	2.0	94
225	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. , 1999, 85, 213.		11
226	Correspondence re: S. Shimoyama et al., increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. <i>Clin. Cancer Res.</i> , 5: 1125-1130, 1999. <i>Clinical Cancer Research</i> , 1999, 5, 3722-3.	3.2	1
227	Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2065-2069.	0.8	155
228	Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1538-1546.	0.8	53
229	Standard versus high-dose therapy in 10+ breast cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 810-811.	0.8	2
230	A decade of clinical investigation in elderly patients with non-Hodgkin's lymphoma: Results as reported in the literature. <i>European Journal of Cancer</i> , 1997, 33, S266-S267.	1.3	0
231	Favourable prognosis after late relapse in Hodgkin's disease. <i>European Journal of Cancer</i> , 1997, 33, S263.	1.3	0
232	Should prophylactic surgery be used in women with a high risk of breast cancer?. <i>European Journal of Cancer</i> , 1997, 33, 2158-2159.	1.3	1
233	Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3178-3184.	0.8	84
234	Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. <i>British Journal of Cancer</i> , 1997, 76, 1215-1220.	2.9	59

#	ARTICLE	IF	CITATIONS
235	Recall Reaction of a Severe Local Peripheral Neuropathy After Paclitaxel Extravasation. Journal of the National Cancer Institute, 1996, 88, 1320-1320.	3.0	10
236	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines.. Endocrinology, 1996, 137, 4322-4330.	1.4	35
237	Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer, 1995, 75, 2147-2152.	2.0	116
238	Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating Factors. Journal of the National Cancer Institute, 1995, 87, 803-808.	3.0	122
239	erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. British Journal of Cancer, 1994, 70, 819-825.	2.9	87
240	Long-Term Survival in Advanced Ovarian Cancer after Cytoreduction and Chemotherapy Treatment. Gynecologic Oncology, 1994, 53, 27-32.	0.6	49
241	Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2287-2291.	3.3	110
242	Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science, 1990, 249, 1552-1555.	6.0	289
243	Mitomycin-C and Vinblastine in Advanced Breast Cancer. Oncology, 1989, 46, 137-142.	0.9	15
244	Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Research and Treatment, 1989, 13, 123-133.	1.1	94
245	Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer, 1989, 64, 1674-1681.	2.0	103
246	Circulating CA 15-3 antigen levels in non-mammary malignancies. British Journal of Cancer, 1989, 59, 283-286.	2.9	50
247	Brain metastases from breast cancer may respond to endocrine therapy. Breast Cancer Research and Treatment, 1988, 12, 83-86.	1.1	20
248	Meningioma preceding breast cancer. Cancer Treatment Reports, 1987, 71, 550-1.	0.5	1
249	Serum Ca 15.3 Levels in Patients with Non-Tumoral Diseases, and Establishment of a Threshold for Tumoral Activity. Results in 1219 Patients. International Journal of Biological Markers, 1986, 1, 159-160.	0.7	16
250	Circulating antigen levels in ovarian cancer.. Journal of Clinical Oncology, 1986, 4, 1148-1149.	0.8	0
251	Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke. Acta Neurologica Scandinavica, 1986, 73, 461-465.	1.0	26
252	Cranial CT scan in transient global amnesia. Acta Neurologica Scandinavica, 1986, 73, 298-301.	1.0	18

#	ARTICLE	IF	CITATIONS
253	CA 15.3: early results of a new breast cancer marker. <i>Anticancer Research</i> , 1986, 6, 683-4.	0.5	16
254	Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	0.6	4
255	Circulating CA 15.3 levels in breast cancer. Our present experience. <i>International Journal of Biological Markers</i> , 1986, 1, 89-92.	0.7	7
256	Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. <i>International Journal of Biological Markers</i> , 1986, 1, 159-60.	0.7	6
257	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. <i>International Journal of Oncology</i> , 0, , .	1.4	14
258	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. , 0, .		5